Ira Winer, MD, PhD, FACOG

home / authors / ira-winer-md-phd-facog

Articles

Ira Winer, MD, PhD, Discusses Next Steps for Nemvaleukin Alfa Plus Pembrolizumab in Ovarian Cancer

May 3rd 2022

Ira Winer, MD, PhD, FACOG, spoke about future directions of nemvaleukin alfa plus pembrolizumab for patients with pretreated platinum resistant ovarian cancer.

Ira Winer, MD, PhD, on Surprising Findings From ARTISTRY-1 in Ovarian Cancer

Ira Winer, MD, PhD, FACOG

April 15th 2022

Ira Winer, MD, PhD, FACOG, spoke about high response rates observed in patients with pretreated platinum-resistant ovarian cancer from the phase 1/2 ARTISTRY-1 trial.

Ira Winer, MD, PhD, Reviews Results of the ARTISTRY-1 Trial in Ovarian Cancer

Ira Winer, MD, PhD, FACOG

April 5th 2022

Ira Winer, MD, PhD, FACOG, spoke about patients with pretreated platinum-resistant ovarian cancer treated with nemvaleukin alfa plus pembrolizumab in the phase 1/2 ARTISTRY-1 trial.

Ira Winer, MD, PhD, Talks Best Data to Come Out of SGO 2022

Ira Winer, MD, PhD, FACOG

March 29th 2022

Ira Winer, MD, PhD, FACOG, spoke about which presentations during The Society of Gynecologic Oncology 2022 Annual Meeting he most enjoyed.